- Location
- Virtual by Zoom
- Series/Type
- DLSPH Partner & Affiliate Event, Faculty/Staff Event, Student Event
- Format
- Online
- Dates
- October 19, 2026 from 12:00pm to 1:00pm
Links
Seminar Overview:
Semaglutide and other GLP-1 receptor agonists (GLP-1 RAs) have rapidly become an important part of the conversation around diabetes and population health. Semaglutide was approved by Health Canada in 2018, and GLP-1 RAs were subsequently covered for adults aged 65 and older through the Ontario Drug Benefit program. However, on January 31, 2024, the Ministry of Health introduced a Limited Use policy that restricted GLP-1 RA coverage.
This seminar presents findings from a population-based descriptive analysis of older adults in Ontario initiating GLP-1 RA medications between 2022 and 2026, with a particular focus on Peel Region. The presentation will explore who is initiating these medications, how patterns of use have changed over time, and what changed following the introduction of the Limited Use policy.
Speaker:
Dr. Hailey Banack, PhD
Dr. Hailey Banack is an Assistant Professor in the Epidemiology Division at the Dalla Lana School of Public Health. She holds a Tier 2 Canada Research Chair in Obesity and Aging Across Populations and the Novo Nordisk Professorship in Health Equity and Chronic Illness Prevention.
Speaker:
Vicki Yiannakis
Vicki Yiannakis is a second-year Master of Public Health student in Epidemiology at the Dalla Lana School of Public Health. This summer, she completed a research practicum through the Network for Healthy Population’s Summer Research and Training Program under the supervision of Dr. Banack and is contributing to ongoing work addressing GLP-1 use in older adults.
